Cisplatin Inhibitors
1 drugsAbout Cisplatin
Cisplatin is a platinum-based chemotherapy drug that binds to DNA, disrupting its structure and inducing cell death, particularly in rapidly dividing cancer cells.
Cisplatin's clinical efficacy in treating various cancers is well-established, though its use is limited by significant side effects; currently, there is no genetic evidence data available linking Cisplatin directly to specific disease predispositions.
There is one FDA-approved drug that targets Cisplatin, PEDMARK, a small molecule used to reduce ototoxicity induced by cisplatin in pediatric patients; FENNEC PHARMS INC is the sole company with an approved drug.
Top Cisplatin Drugs
FENNEC PHARMS INC is the only company with an approved drug targeting Cisplatin.
Low competition suggests high barriers to entry or limited market attractiveness.
Cisplatin Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Cisplatin, using small molecule modality.
The lack of diverse modalities indicates a whitespace opportunity for novel therapeutic approaches.
Cisplatin Clinical Trials 27 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Cisplatin. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 7 | 2 | 2 | 3 | 50% |
| Phase 2 | 13 | 8 | 2 | 3 | 80% |
| Phase 3 | 6 | 1 | 2 | 3 | 33% |
| Phase 4 | 1 | 0 | 1 | 0 | 0% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Cisplatin Drug Approval Timeline (2022 - 2022)
The first and most recent drug approval was PEDMARK in 2022.
Recent approval suggests renewed interest, but saturation may occur quickly with limited innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 24 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Cisplatin. A trial counts if an approved drug acting on Cisplatin is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.